MX2023013065A - Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso. - Google Patents
Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso.Info
- Publication number
- MX2023013065A MX2023013065A MX2023013065A MX2023013065A MX2023013065A MX 2023013065 A MX2023013065 A MX 2023013065A MX 2023013065 A MX2023013065 A MX 2023013065A MX 2023013065 A MX2023013065 A MX 2023013065A MX 2023013065 A MX2023013065 A MX 2023013065A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- conductance potassium
- potassium channel
- disease
- compositions
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 102000004257 Potassium Channel Human genes 0.000 title abstract 4
- 108020001213 potassium channel Proteins 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183717P | 2021-05-04 | 2021-05-04 | |
| PCT/US2022/027637 WO2022235771A1 (en) | 2021-05-04 | 2022-05-04 | Large-conductance potassium channel modulators, compositions thereof, methods of manufacturing thereof, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013065A true MX2023013065A (es) | 2024-01-03 |
Family
ID=83932518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013065A MX2023013065A (es) | 2021-05-04 | 2022-05-04 | Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240238303A1 (https=) |
| EP (1) | EP4333852A4 (https=) |
| JP (1) | JP2024516730A (https=) |
| KR (1) | KR20240004887A (https=) |
| CN (1) | CN117479945A (https=) |
| AU (1) | AU2022270648A1 (https=) |
| BR (1) | BR112023023075A2 (https=) |
| CA (1) | CA3217887A1 (https=) |
| MX (1) | MX2023013065A (https=) |
| WO (1) | WO2022235771A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1330426A4 (en) * | 2000-10-13 | 2005-09-14 | Bristol Myers Squibb Co | SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE |
| ATE488231T1 (de) * | 2002-12-23 | 2010-12-15 | Icagen Inc | Quinazolinone als kaliumkanalmodulatoren |
| JP2007505158A (ja) * | 2003-05-21 | 2007-03-08 | ボード オブ リージェンツ ザ ユニバーシティー オブ テキサス システム | 心肥大および心不全の処置としてのプロテインキナーゼＣ−μ（ＰＫＤ）の阻害 |
| US20090111868A1 (en) * | 2004-12-02 | 2009-04-30 | Marx Steven O | Use Of Rottlerin And Its Derivatives As Activators Of BK Channel For Therapy Of Hypertension And Related Disorders |
| US8399663B2 (en) * | 2009-04-03 | 2013-03-19 | Astellas Pharma Inc. | Salt of 1,3,5-triazine-2,4,6-triamine derivative |
| US20100256152A1 (en) * | 2009-04-03 | 2010-10-07 | Astellas Pharma Inc. | Novel pharmaceutical composition for treatment of schizophrenia |
| GB201011905D0 (en) * | 2010-07-15 | 2010-09-01 | Unilever Plc | Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates |
| AU2011336764B2 (en) * | 2010-11-29 | 2017-02-23 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| US20120295911A1 (en) * | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| CN102093364B (zh) * | 2011-01-07 | 2015-01-28 | 北京赛林泰医药技术有限公司 | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 |
| US8945605B2 (en) * | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
| SG11201407964YA (en) * | 2012-05-29 | 2014-12-30 | Galleon Pharmaceuticals Inc | Novel compounds and compositions for treatment of breathing control disorders or diseases |
| SG11201503505QA (en) * | 2012-11-15 | 2015-06-29 | Galleon Pharmaceuticals Inc | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
| GB201408119D0 (en) * | 2014-05-08 | 2014-06-25 | Univ Cork | Method |
| WO2018007331A1 (en) * | 2016-07-08 | 2018-01-11 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives |
| WO2018011164A1 (en) * | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives |
| CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
-
2022
- 2022-05-04 EP EP22799485.2A patent/EP4333852A4/en active Pending
- 2022-05-04 MX MX2023013065A patent/MX2023013065A/es unknown
- 2022-05-04 CN CN202280040049.2A patent/CN117479945A/zh active Pending
- 2022-05-04 JP JP2023568446A patent/JP2024516730A/ja active Pending
- 2022-05-04 US US18/289,288 patent/US20240238303A1/en active Pending
- 2022-05-04 BR BR112023023075A patent/BR112023023075A2/pt unknown
- 2022-05-04 AU AU2022270648A patent/AU2022270648A1/en active Pending
- 2022-05-04 KR KR1020237041640A patent/KR20240004887A/ko active Pending
- 2022-05-04 WO PCT/US2022/027637 patent/WO2022235771A1/en not_active Ceased
- 2022-05-04 CA CA3217887A patent/CA3217887A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117479945A (zh) | 2024-01-30 |
| KR20240004887A (ko) | 2024-01-11 |
| BR112023023075A2 (pt) | 2024-01-30 |
| EP4333852A1 (en) | 2024-03-13 |
| EP4333852A4 (en) | 2025-03-26 |
| CA3217887A1 (en) | 2022-11-10 |
| AU2022270648A1 (en) | 2023-12-07 |
| US20240238303A1 (en) | 2024-07-18 |
| JP2024516730A (ja) | 2024-04-16 |
| WO2022235771A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
| MX2019011530A (es) | Saxitoxinas 11,13-modificadas para el tratamiento del dolor. | |
| WO2019055880A3 (en) | Method of administration and treatment | |
| EP4706638A3 (en) | Methods of treating heart failure by administering omecamtiv mecarbil | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| MX2022012739A (es) | Derivados de piridopirimidinona y su uso como moduladores del receptor de hidrocarburos de arilo. | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| WO2019157495A3 (en) | Methods for preventing and/or treating bone loss conditions by modulating irisin | |
| MX2021010058A (es) | Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel. | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| WO2025024305A3 (en) | Irak4 degraders and uses thereof | |
| MX2022011826A (es) | Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. | |
| MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
| MX2023014131A (es) | Derivado de 7-nitro-8-hidroxiquinolina, metodo de preparacion y uso medico del mismo. | |
| WO2023043870A8 (en) | Chewing gum formulation of lsd and methods of use thereof | |
| EP4623999A3 (en) | Sotorasib for use in the treatment of cancer | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2021012353A (es) | Composicion cosmetica topica y usos de la misma. | |
| MX2023013065A (es) | Moduladores de canales de potasio de gran conductancia, composiciones de estos, métodos para su fabricación y métodos para su uso. | |
| MX2022011171A (es) | Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos. | |
| WO2022081610A8 (en) | TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR | |
| WO2020025657A9 (en) | Composition for use in the prevention and/or treatment of the genitourinary mucosa | |
| MX2024009559A (es) | Métodos de tratamiento mediante el uso de moduladores del canal de calcio tipo t. |